NCT01437423View on ClinicalTrials.gov

Regulatory Post-Marketing Surveillance Study for TETRAXIM™

PHASE4CompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
DiphtheriaTetanusPertussisPoliomyelitis
Interventions
BIOLOGICAL

TETRAXIM™: Combined adsorbed diphtheria, tetanus, acellular pertussis and enhanced inactivated polio

0.5 mL, Intramuscular at 2, 4, 6 months (Primary) or at 4 to 6 years (Booster) vaccination

Trial Locations (1)

Unknown

Seoul

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT01437423 - Regulatory Post-Marketing Surveillance Study for TETRAXIM™ | Biotech Hunter | Biotech Hunter